Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
-
- Mark C. Petrie
- British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom
-
- Subodh Verma
- Division of Cardiac Surgery, St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada
-
- Kieran F. Docherty
- British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom
-
- Silvio E. Inzucchi
- Section of Endocrinology, Yale University School of Medicine, New Haven, Connecticut
-
- Inder Anand
- Department of Cardiology, University of Minnesota, Minneapolis
-
- Jan Belohlávek
- Second Department of Internal Medicine, Cardiovascular Medicine, General Teaching Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic
-
- Michael Böhm
- Department of Medicine, Saarland University Hospital, Homburg/Saar, Germany
-
- Chern-En Chiang
- Division of Cardiology, Taipei Veterans General Hospital, Taipei, Taiwan
-
- Vijay K. Chopra
- Department of Cardiology, Medanta, Gurgaon, Haryana, India
-
- Rudolf A. de Boer
- Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
-
- Akshay S. Desai
- Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
-
- Mirta Diez
- Division of Cardiology, Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina
-
- Jaroslaw Drozdz
- Department Cardiology, Medical University of Lodz, Lodz, Poland
-
- Andre Dukát
- Fifth Department of Internal Medicine, Comenius University in Bratislava, Bratislava, Slovakia
-
- Junbo Ge
- Shanghai Institute of Cardiovascular Disease, Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai, China
-
- Jonathan Howlett
- Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
-
- Tzvetana Katova
- Clinic of Cardiology, National Cardiology Hospital, Sofia, Bulgaria
-
- Masafumi Kitakaze
- Cardiovascular Division of Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan
-
- Charlotta E. A. Ljungman
- Institute of Medicine, Department of Molecular and Clinical Medicine/Cardiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
-
- Béla Merkely
- Heart and Vascular Center, Semmelweis University, Budapest, Hungary
-
- Jose C. Nicolau
- Instituto do Coracao (InCor), Hospital das Clínicas Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
-
- Eileen O'Meara
- Department of Cardiology, Montreal Heart Institute, Montreal, Ontario, Canada
-
- Pham Nguyen Vinh
- Department of Internal Medicine, Tan Tao University, Tan Duc, Vietnam
-
- Morten Schou
- Department of Cardiology, Gentofte University Hospital Copenhagen, Copenhagen, Denmark
-
- Sergey Tereshchenko
- Department of Myocardial Disease and Heart Failure, National Medical Research Center of Cardiology, Moscow, Russia
-
- Lars Køber
- Department of Cardiology Copenhagen University Hospital, Copenhagen, Denmark
-
- Mikhail N. Kosiborod
- St Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City
-
- Anna Maria Langkilde
- Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
-
- Felipe A. Martinez
- Universidad Nacional de Córdoba, Córdoba, Argentina
-
- Piotr Ponikowski
- Center for Heart Diseases, University Hospital, Wroclaw Medical University, Wroclaw, Poland
-
- Marc S. Sabatine
- Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
-
- Mikaela Sjöstrand
- Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
-
- Scott D. Solomon
- Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
-
- Per Johanson
- Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
-
- Peter J. Greasley
- Early Discovery and Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
-
- David Boulton
- Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland
-
- Olof Bengtsson
- Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
-
- Pardeep S. Jhund
- British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom
-
- John J. V. McMurray
- British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom
収録刊行物
-
- JAMA
-
JAMA 323 (14), 1353-, 2020-04-14
American Medical Association (AMA)